Searle & Co’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Searle & Co’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13,200	Closed	-$13K	–	137
2018 Q3	$13K	Sell	13,200 -125	-0.9%	-$209	0.01%	132
2018 Q2	$32K	Hold	13,325	–	–	0.02%	130
2018 Q1	$32K	Hold	13,325	–	–	0.02%	133
2017 Q4	$32K	Sell	13,325 -3,925	-23%	-$10.9K	0.02%	130
2017 Q3	$54K	Hold	17,250	–	–	0.04%	125
2017 Q2	$69K	Hold	17,250	–	–	0.05%	125
2017 Q1	$64K	Buy	+17,250	New	+$54.1K	0.04%	130
2016 Q4	–	Sell	-17,250	Closed	-$105K	–	118
2016 Q3	$105K	Buy	+17,250	New	+$106K	0.09%	112
2016 Q2	–	Sell	-17,250	Closed	-$179K	–	107
2016 Q1	$179K	Hold	17,250	–	–	0.16%	106
2015 Q4	$500K	Hold	17,250	–	–	0.48%	60
2015 Q3	$545K	Buy	+17,250	New	+$825K	0.56%	55

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MFGP

Marshall Financial Group (Pennsylvania) Doylestown, Pennsylvania $364M AUM 12.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Searle & Co's PTX Position: Q4 2018 in Review

Searle & Co sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2018, closing a stake of 13,200 shares — an estimated $13K sold.

Searle & Co first reported a position in PTX in Q3 2015 and held it in 11 quarters. The position peaked at $545K in Q3 2015. 32 funds tracked by Wall St. Rank hold PTX as of Q4 2018.

Searle & Co reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
Searle & Co sold 13,200 Pernix Therapeutics Holdings, Inc. shares in Q4 2018, an estimated $13K.
Searle & Co first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2015 and held it in 11 quarters.
Searle & Co's Pernix Therapeutics Holdings, Inc. position peaked at $545K in Q3 2015.
32 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2018.

Based on Searle & Co's 13F filing for Q4 2018, filed 12 Feb 2019.